Judah Frommer
Stock Analyst at Morgan Stanley
(3.16)
# 1,079
Out of 4,905 analysts
186
Total ratings
60%
Success rate
6.85%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $20.04 | +29.74% | 2 | Jul 2, 2025 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $102 → $129 | $129.46 | -0.36% | 2 | Jun 5, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $22.97 | +87.20% | 2 | May 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $10.34 | +16.05% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.69 | +176.18% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $30.68 | -28.29% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $4.36 | +37.61% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $70.95 | +49.40% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $11.65 | +200.43% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.50 | +420.00% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $3.52 | -14.77% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $3.37 | +1,086.94% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.48 | +778.38% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $34.04 | -11.87% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $12.36 | +86.16% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $48.53 | +3.03% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $21.97 | +541.78% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.26 | +931.75% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $2.79 | +222.58% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $21.98 | +0.09% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $6.92 | +1.16% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.94 | +0.76% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $23.62 | +94.75% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.24 | +464.52% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $15.20 | +261.84% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $104.17 | -55.84% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $99.13 | -50.57% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $953.91 | -61.21% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $83.77 | -62.99% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $77.91 | -2.45% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $109.23 | +66.62% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $108.15 | -1.06% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $131.89 | -27.97% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $20.24 | -11.07% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $139.67 | -16.95% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $105.18 | -63.87% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $169.61 | -87.03% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $72.22 | -51.54% | 9 | Apr 29, 2020 |
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $20.04
Upside: +29.74%
Blueprint Medicines
Jun 5, 2025
Maintains: Equal-Weight
Price Target: $102 → $129
Current: $129.46
Upside: -0.36%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $22.97
Upside: +87.20%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $10.34
Upside: +16.05%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.69
Upside: +176.18%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $30.68
Upside: -28.29%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $4.36
Upside: +37.61%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $70.95
Upside: +49.40%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $11.65
Upside: +200.43%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.50
Upside: +420.00%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $3.52
Upside: -14.77%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $3.37
Upside: +1,086.94%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.48
Upside: +778.38%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $34.04
Upside: -11.87%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $12.36
Upside: +86.16%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $48.53
Upside: +3.03%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $21.97
Upside: +541.78%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.26
Upside: +931.75%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $2.79
Upside: +222.58%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $21.98
Upside: +0.09%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $6.92
Upside: +1.16%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.94
Upside: +0.76%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $23.62
Upside: +94.75%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.24
Upside: +464.52%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $15.20
Upside: +261.84%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $104.17
Upside: -55.84%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $99.13
Upside: -50.57%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $953.91
Upside: -61.21%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $83.77
Upside: -62.99%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $77.91
Upside: -2.45%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $109.23
Upside: +66.62%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $108.15
Upside: -1.06%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $131.89
Upside: -27.97%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $20.24
Upside: -11.07%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $139.67
Upside: -16.95%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $105.18
Upside: -63.87%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $169.61
Upside: -87.03%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $72.22
Upside: -51.54%